27.7 C
New York
Wednesday, June 10, 2026

Tag: society

newssourceFORcompanyinformationcontent1marketreleases

Hitachi and Intel announce strategic collaboration to accelerate AI transformation across key industries

TOKYO and SANTA CLARA, Calif., June 5, 2026 /PRNewswire/ -- Hitachi, Ltd. (TSE:6501, "Hitachi") and Intel Corporation (NASDAQ: INTC, "Intel") today announced a strategic collaboration...

Hitachi and Intel announce strategic collaboration to accelerate AI transformation across key industries

TOKYO and SANTA CLARA, Calif., June 5, 2026 /PRNewswire/ -- Hitachi, Ltd. (TSE:6501, "Hitachi") and Intel Corporation (NASDAQ: INTC, "Intel") today announced a strategic collaboration...

Hitachi and Intel announce strategic collaboration to accelerate AI transformation across key industries

TOKYO and SANTA CLARA, Calif., June 5, 2026 /CNW/ -- Hitachi, Ltd. (TSE:6501, "Hitachi") and Intel Corporation (NASDAQ: INTC, "Intel") today announced a strategic collaboration...

UTGL Donates HK$650,000 to Advance Anti-Aging, Cardiovascular Health and Healthy Longevity Through Corporate Social Responsibility and Clinical Research

HONG KONG, June 5, 2026 /PRNewswire/ -- UniTrust Global Limited | UTGL announced a donation of HK$650,000 to Prime Healthcare Medical Services Limited in...

Chiesi Global Rare Diseases Announces European Commission Approval of LOJUXTA® (lomitapide) ▼ Capsules for Paediatric Use in Homozygous Familial Hypercholesterolaemia (HoFH)

European Commission approval expands the indication of lomitapide in the European Union (EU) to include children 5 years of age and older with HoFH, an ultra-rare genetic disorder affecting LDL-cholesterol levels 
European Commission approval expands the indication of lomitapide in the European Union (EU) to include children 5 years of age and older with HoFH, an ultra-rare genetic disorder affecting LDL-cholesterol levels

Mabwell’s 9MW5211 Receives IND Clearance from NMPA for Inflammatory Bowel Disease

SHANGHAI, June 4, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that its independently developed innovative...

Lundbeck presents positive Phase IIb data for bocunebart (Lu AG09222; anti-PACAP mAb) in migraine prevention at the AHS congress

The intravenous part of the Phase IIb clinical dose-finding trial PROCEED met its primary endpoint, with bocunebart demonstrating a statistically significant reduction in monthly...

Wheaton Precious Metals Launches Third Annual $1 Million Future of Mining Challenge Focused on Mine Optimization and Reducing Land Impacts

VANCOUVER, BC, June 4, 2026 /PRNewswire/ - Advancing into its third year, Wheaton Precious Metals™ Corp. ("Wheaton" or the "Company") is pleased to announce the...

Wheaton Precious Metals Launches Third Annual $1 Million Future of Mining Challenge Focused on Mine Optimization and Reducing Land Impacts

VANCOUVER, BC, June 4, 2026 /CNW/ - Advancing into its third year, Wheaton Precious Metals™ Corp. ("Wheaton" or the "Company") is pleased to announce the...

PRSA-LA Announces Call for Entries for Its 62nd Annual PRism Awards

The premier awards program for the Greater Los Angeles public relations community is now accepting submissions to honor the year’s most innovative and impactful campaigns 
The premier awards program for the Greater Los Angeles public relations community is now accepting submissions to honor the year’s most innovative and impactful campaigns

Tishman Speyer Secures $300 Million First Close for Korea Living Venture with APG and Bouwinvest

European Pension Investors Back Strategy Focused on Korea's Rapidly Expanding Rental Housing MarketNEW YORK, June 4, 2026 /PRNewswire/ -- Tishman Speyer today announced the...

Aarti Industries Achieves EcoVadis Platinum Rating 2026, Ranking Among the Top 1% of Companies Globally

EcoVadis score rises to 87/100, reflecting a decade-long sustainability journey and reinforcing Aarti's position among the world's leading sustainability performers.MUMBAI, India, June 4, 2026...

2026 ASCO LBA | Juncell Therapeutics’ GC101 TIL Therapy Achieves Primary Endpoint in the Pivotal Phase II Trial for PD-1 Antibody Failed Advanced Melanoma

SHANGHAI, June 3, 2026 /PRNewswire/ -- On June 1 (Chicago time), in a Late-Breaking Abstract (LBA) oral presentation at the 2026 American Society of Clinical...

Transcontinental Inc. Announces Results for the Second Quarter of Fiscal Year 2026

Résultats pour le deuxième trimestre 2026

- A word from our sponsors -

spot_img
HomeTagsSociety

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers